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The “year in review” session is a key moment of the Osteoarthritis Research Society International (OARSI)
Congress. This is a unique opportunity for opinion leaders to summarize and comment the recent
advances in one particular ﬁeld of osteoarthritis research. This review is a summary of selected studies
related to soluble biomarkers published between September 1st, 2010 and August 30th, 2011 and
identiﬁed by a pubmed search using the terms “biomarkers” and “osteoarthritis”. In addition, I have
selected some works presented during the 2011 OARSI Congress. This year was dominated by the
publication of a consensus paper on the qualiﬁcation of osteoarthritis (OA) biomarkers by the OARSI/
Food Drug Administration (FDA) Osteoarthritis Biomarkers Working Group, and of proteomes of chon-
drocyte vesicles, urine and serum.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The development of new treatments for osteoarthritis (OA) is
disabled by the lack of a good primary clinical outcome for
measuring cartilage structural changes. Until now, the gold stan-
dard was the measurement of joint space width on standard X-ray.
This parameter lacks of sensitivity and reproducibility and fails to
detect the early metabolic changes preceding the appearance of
structural changes. As a consequence, to assess structural changes
in clinical trials requires a large population and a long-term follow-
up. The academic and industrial researchers need of new tools for
detecting the early metabolic changes occurring in joint tissues
before the appearance of imaging lesions. The development of
these tools will allow healthcare providers to administer treatment
earlier and potentially improve efﬁcacy. Healthcare providers also
need tools to identify fast progressors and more sensitive means to
evaluate response to treatment. This personalized medicine
approachwill contribute to the improvement of quality and efﬁcacy
of the OA patient management.
Soluble biomarkers are good candidate to ﬁt these purposes. The
scientiﬁc community’s interest in OA biochemical markers has
increased during the last decade. The number of paper published in
this ﬁeld between 2000 and 2010 has increased ﬁve-fold (Fig. 1).
This review sought to highlight some biomarker studies published: Y. Henrotin, University of
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s Research Society International. Pover the prior year, since the 2010 meeting of the Osteoarthritis
Research Society International (OARSI) in Brussels and referenced
in the pubmed database. This is not a systematic review and the
paper selection was based on the expert opinion of the author.
OARSI/FDA Osteoarthritis Biomarkers Working group
white paper
This year 2011 was marked by the publication of a consensus
document for the application of in vitro (biochemical and other
soluble) biomarkers in the development of drugs for OA by the
OARSI/Food Drug Administration (FDA) biomarkers working
groups1. This group attempts to respond to speciﬁc questions posed
by the FDA. The OARSI/FDA working group document summarizes
deﬁnition and classiﬁcation systems for biomarkers, applications
and potential utility of biomarkers for development of OA thera-
peutics, provides guidelines for biomarkers qualiﬁcation and
a research agenda to advance the science of OA-related research.
This guide gives also precise advices for sample acquisition and
handling and a glossary of the term related to biomarker research.
This paper should be a reference for researchers working in the
biomarker research ﬁeld.
Biological ﬂuid proteomes as sources of new biomarkers
The proteomic corresponds to a wide variety of techniques to
study the protein content of cells, tissues or biological ﬂuids and to
isolate proteins of interest. This approach allows the identiﬁcation
of new biomarkers by comparing the proteome of normal andublished by Elsevier Ltd. All rights reserved.
Fig. 1. Yearly number of papers in pubmed database identiﬁed by introducing the
research words “biomarkers” and “osteoarthritis”.
Y. Henrotin / Osteoarthritis and Cartilage 20 (2012) 215e217216disease affected biological material. This year, papers describing the
proteomes of OA chondrocytes vesicles, urine and serum have been
published. In serum, De Seny et al.2 have identiﬁed four novel
biomarkers for OA: V65 vitronectin fragment, cf3 peptide,
Connective Tissue-Activating Peptide III (CTAPIII) and an unknown
protein. V65 vitronectin fragment and cf3, a fragment of C3b, were
found to be expressed at higher levels in sera of OA patients
compared to controls subjects and patients with rheumatoid
arthritis, and that wathever the radiological severity of OA. CTAPIII
was signiﬁcantly lower in the OA patients population compared to
control subjects, and among OA subsets, CTAPIII remained signiﬁ-
cantly reduced in OA patients with the worst radiographic disease.
Mass spectrometry analysis identiﬁed 13 proteins with an
abundance decreased or increased by more than 1.5 fold in urine of
OA patients compared to normal subjects3. The proteins found to be
increased in urineweremainly b-actin, a1-microglobulin, ﬁbulin-3,
apoptosis-inducing factor-2 and the Zn-a2-glycoprotein precursor
and the decreased proteins were serpin b1 and b3, mannan binding
lectin serine protease-2 precursor, kinninogen-1 precursor and
a1-antitrypsin. Interestingly, two mostly increased spots in the
proteome of OA patients contained speciﬁc sequences of ﬁbulin-3
(so called Fib3-1 and Fib3-2), the only extracellular matrix protein
found to be signiﬁcantly modiﬁed in the proteome of urine of OA
patients. Fibulin-3 is widely distributed in various tissues. The
protein is also present in blood vessels of different sizes, and is
capable of inhibiting vessel development and angiogenesis both
in vitro and in vivo4. During development, the protein is expressed in
themesenchyme giving rise to cartilage and bone, and plays a role in
organizing the development of skeletal system5.Moreover,ﬁbulin-3
is intimately associated with Tissue Inhibitor of MetalloProteases
(TIMPs)-3, an inhibitor of metalloproteinases involved in the path-
ogenesis of OA6e8. The overexpression of ﬁbulin-3 suppressed
chondrocyte differentiation by inhibition of cartilage nodule
formation, proteoglycan production, matrix gene expression9.
Articular cartilage vesicles (ACVs) are extracellular organelles
found in normal articular cartilage. Rosenthal et al.10 have analyzed
the proteome of these vesicles from normal and OA human carti-
lage. Six proteins were found only in normal ACVs, while nine
proteins were seen exclusively in OA ACVs. Many of the proteins
that were exclusive to OA, such as ﬁbrinogen, complement,
immunoglobulins, and apolipoproteins, are typical markers of
inﬂammation. Levels of nine proteins were signiﬁcantly increased
in OA ACVs including transforming growth factor b-induced
protein big-H3, integring-binding protein DEL-1, serum amyloid
P-component precursor and vitronectin precursor. The primary rolefor ACVs was in the pathologic mineralization of cartilage. The
presence of inﬂammation markers in OA ACVs supports a role of
ACVs in OA-related inﬂammation.
New potential biomarkers for OA research
We have developed new immunoassays for measuring in serum
two fragments of ﬁbulin-3, so called Fib3-1 and Fib3-23. By
comparison with age-matched healthy subjects, these epitopes
were found to be elevated in serum of OA patients. They discrimi-
nate between OA and normal populations with high speciﬁcity and
sensitivity, indicating that these fragments are good diagnostic
biomarkers. Of course, this needs to be conﬁrmed in independent
trials.
CIIM was an MMP-released neo-epitope located in the
C-terminal area of the triple helicoidal part of the type II collagen
molecule11. Mean serum CIIM was signiﬁcantly higher in individ-
uals with mild and severe OA than in younger individuals without
OA. However, the advantages of this new biomarker over existing
type II collagen biomarkers, like Coll2-1 or C2C, should be
demonstrated.
D-COMP is a desaminated cartilage oligomeric matrix protein
(COMP) biomarker12. Interestingly, in 450 participants from the
Johnstone County osteoarthritis project, D-COMP was associated
with hip but not knee OA severity as deﬁned by increasing
KellgreneLawrence (KL) grade. In contrast, total COMP was asso-
ciated with knee but not hip K&L grade. D-COMP is the ﬁrst
biomarker to show speciﬁcity for a particular joint site.
Advances in OA biomarkers qualiﬁcation
Obesity is the main modiﬁable risk factor for the onset of the
knee. The observation that obesity is also a risk factor for OA of non-
weight bearing joints such as the hand has suggested that the link
between obesity and OA might also occur through systemic
inﬂammation. Richette et al.13 have demonstrated that a massive
weigh loss (>10%) after bariatric surgery improved pain and func-
tion in obese patients with knee OA. As expected, weight loss
resulted in a signiﬁcant increase in serum levels of adiponectin and
a signiﬁcant decrease in that of leptin and inﬂammatory markers
like interleukin(IL)-6, hs C-Reactive Protein (CRP), orosomucoid and
ﬁbrinogen. In parallel, massive weight loss resulted in a signiﬁcant
increase in the level of PIIANP, a marker of type II collagen
synthesis, and a decrease in that of COMP, a marker of cartilage
degradation. These results are the ﬁrst which associate weight loss
and cartilage biomarkers, helping us to understand disease and the
link between obesity and arthritis.
Several studies have found an association of uric acid and OA.
Based on these previous observations, Denoble et al.14 have
postulated that uric acid could increase risk for OA through
inﬂammasome activation. In this cohort of subjects with knee OA,
synovial ﬂuid uric acid was strongly and positively correlated with
OA severity evaluated by both radiograph and bone scintigraphy
and with two inﬂammatory cytokines IL-18 and IL-1b. They
conclude that uric acid is a marker of knee OA severity.
The relationship between biomarkers levels and incident
radiographic OA has been poorly investigated. Recently, Golightly
et al.15 have reported that higher baseline COMP and hyaluronic
acid serum levels predicted incident joint space narrowing and
higher COMP levels predicted incident knee osteophytes. These
results represent detection of a molecular stage of OA prior of
radiographic manifestation.
In an exploratory study, Eckstein et al.16 compared a large set of
molecular markers in biological ﬂuids between knees with or
without structural progression, usingMRI-based cartilage loss as an
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(including uCTX-II, uTUNE, s COMP, sPIINP, etc) investigated were
associated with longitudinal cartilage thinning in radiographic
knee OA In contrast, Berry et al17 found that low level (less than the
mean) but not high level (greater than or equal to the mean) of
COMP and PIIANP, but not C2C, were associated with reduced
medial cartilage volume loss over 2 years. PIIANP was also associ-
ated with a signiﬁcantly reduced risk of knee joint replacement. In
the Pelletier’s phase III clinical trial in patients with knee OA18,
higher baseline values of IL-6, CRP and COMP were predictive of
cartilage volume loss over 2 years. However, over time a reduction
in MMP-1 and MMP-3 levels correlated best with reduction in
volume loss and the effect of licofelone, a COX/LOX inhibitor,
OARSI OA Biomarkers Global initiative
The OARSI OA Biomarker Global Initiative aims to develop
biomarkers by creating a consortium of researchers, managing
research projects and organizing a series of mini-symposium and
workshops. Amini-symposiumwas organizedduring the 2011OARSI
Congress. The goal of this mini-symposium was to exchange recent
information and ideas among members of the biomarkers commu-
nity. This mini-symposium was marked by the presentation of the
Foundation for theNHI (fNHI) biomarkersproject aiming to assess the
responsiveness of the OA biochemical and imaging markers and to
establish thepredictive validityof thesebiomarkersusing thedata set
of NHI funded multi-center longitudinal, prospective, observational
study of knee OA. This 2.5-years project will assess 13 biochemical
markers including hyaluronan, COMP, collagen I and II epitopes,
aggrecan andMMP-3 in serum and urine of knee OA patients. A third
workshop will be held July 12e14 2012 in South Carolina and will
cover biochemical biomarkers and radiological imaging.
Concluding remarks
Research in OA biomarkers is in a growing phase stimulated by
the OARSI OA Biomarker Global Initiative and industry who are
expecting new tools to accelerate drug discovery and development.
We speculate that biomarkers predictive of OA progression at the
individual level will be available in the near future. These
biomarkers will be helpful for the development of personalized
management for the treatment of OA patients. The early detection
of the progressor patients will allow preventative approach for
managing the disease and a better use of the existing therapeutic
modalities. Many biomarkers are tested as companion biomarkers
by industry to rapidly detect patients who respond to a particular
treatment. This attractive approach will be helpful to increase the
efﬁcacy of the OA pharmacological management and probably to
better control drug consumption.
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